China's Innovation Moment
From cross-border deals to NewCos, faster clinical data for quality assets is fueling the China innovation story, turning biopharmas from Shanghai to Beijing into global players. The next milestone for China's biotechs will be generating first-order innovation that competes on a global scale — innovation driven by executives seasoned at MNCs and re-invigorated by homegrown and next-gen talent. Multinational pharma and Western VCs have been the first to capitalize on China's rise, sourcing innovation from China at record levels. But testing faster in humans is also a recipe for Western and Asia biotechs outside of China to de-risk their own compounds, working with China partners.
This November, BioCentury, BayHelix and Insights Partner McKinsey & Company invite you to visit Shanghai for the 13th China Healthcare Summit. Get a firsthand look at China's biotech ecosystem and build your network with the right biopharmas, investors and CDMOs.